Please use this identifier to cite or link to this item: doi:10.22028/D291-35965
Title: Upregulation of PSMA Expression by Enzalutamide in Patients with Advanced mCRPC
Author(s): Rosar, Florian
Neher, Robert
Burgard, Caroline
Linxweiler, Johannes
Schreckenberger, Mathias
Hoffmann, Manuela A.
Bartholomä, Mark
Khreish, Fadi
Ezziddin, Samer
Language: English
Title: Cancers
Volume: 14
Issue: 7
Publisher/Platform: MDPI
Year of Publication: 2022
Free key words: prostate cancer
DDC notations: 610 Medicine and health
Publikation type: Journal Article
Abstract: In this study, we investigated upregulation of prostate-specific membrane antigen (PSMA) by enzalutamide in a cohort (n = 30) of patients with advanced metastatic castration-resistant prostate cancer (mCRPC). Patients were examined by [68Ga]Ga-PSMA-11 PET/CT pre- and post-enzalutamide medication (mean 13 ± 7 days). Imaging results were compared based on quantification of wholebody PSMA tumor burden: total lesion PSMA (TLP) and normalized TLP values to liver (TLP-LR) and to parotid gland (TLP-PR). In addition, lesion-based analyses were performed. The median (mean) increases in TLP, TLP-LR and TLP-PR after enzalutamide medication were 10.1% (20.2%), 29.5% (34.8%) and 27.6% (24.4%), respectively. These increases were statistically significant (p = 0.002, p < 0.001, and p < 0.001), while prostate-specific antigen (PSA) serum values did not change significantly (p = 0.483). The increase was independent of prior patient exposure to enzalutamide. SUVmax increased substantially (>10%) in 49.6% of target lesions. The relative change was significantly higher in the subgroup of lesions with SUVmax < 10 (p < 0.001). In conclusion, short-term enzalutamide medication significantly increases PSMA expression in patients with mCRPC, irrespective of prior enzalutamide exposure. The relative PSMA upregulation effect seems to be more pronounced in lesions with only moderate baseline PSMA expression. Enzalutamide may provide a potential enhancer medication for PSMA-targeted radioligand therapy.
DOI of the first publication: 10.3390/cancers14071696
Link to this record: urn:nbn:de:bsz:291--ds-359650
ISSN: 2072-6694
Date of registration: 12-Apr-2022
Faculty: M - Medizinische Fakultät
Department: M - Radiologie
M - Urologie und Kinderurologie
Professorship: M - Prof. Dr. Samer Ezziddin
M - Keiner Professur zugeordnet
Collections:SciDok - Der Wissenschaftsserver der Universität des Saarlandes

Files for this record:
File Description SizeFormat 
cancers-14-01696-v2.pdf1,99 MBAdobe PDFView/Open

This item is licensed under a Creative Commons License Creative Commons